Doorley Laura A, Meza-Perez Vanessa, Jones Sarah J, Rybak Jeffrey M
Department of Pharmacy and Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
J Infect Dis. 2025 Jun 17. doi: 10.1093/infdis/jiaf285.
Mutations in the Candidozyma (Candida) auris β-glucan synthase gene (FKS1) altering S639 are frequently associated with clinical echinocandin resistance. We have developed a novel C auris-optimized episomal plasmid-induced Cas9 (EPIC) gene-editing system capable of recyclable precision editing and demonstrate the contribution of FKS1S639F mutation to echinocandin resistance.
The EPIC gene-editing system was generated for optimized use in C auris, and ADE2 modification was evaluated in 5 C auris clades. Mutations leading to Fks1S639F and Fks1WT were placed into echinocandin-susceptible and echinocandin-resistant isolates from clades III and I, respectively. Echinocandin susceptibility was determined by Clinical and Laboratory Standards Institute methods. Cell wall abundance of chitin and β-glucan was assessed by staining with calcofluor white and aniline blue.
The EPIC system was capable of targeted ADE2 editing in all tested C auris isolates and precise editing confirmed by sequencing. A single-nucleotide polymorphism (SNP) in FKS1 resulting in either the S639F substitution or a synonymous mutation was introduced in an echinocandin-susceptible clade III isolate. Precision FKS1 editing by the EPIC system was confirmed by whole genome sequencing. Introduction of the Fks1S639F allele increased echinocandin resistance, while correction of the Fks1S639F to the Fks1WT sequence in an echinocandin-resistant clade I isolate restored echinocandin sensitivity. Evaluation of cell wall composition showed strains harboring Fks1S639F to contain significantly elevated β-glucan and chitin content.
These data demonstrate the potential of our EPIC system in its ability to introduce SNPs in multiple C auris clade backgrounds while revealing the direct impact of the S639F-encoding FKS1 mutation on echinocandin resistance.
耳念珠菌β-葡聚糖合酶基因(FKS1)中改变S639的突变常与临床棘白菌素耐药性相关。我们开发了一种新型的针对耳念珠菌优化的附加体质粒诱导型Cas9(EPIC)基因编辑系统,该系统能够进行可循环的精确编辑,并证明了FKS1S639F突变对棘白菌素耐药性的作用。
构建了用于耳念珠菌优化使用的EPIC基因编辑系统,并在5个耳念珠菌分支中评估了ADE2修饰。分别将导致Fks1S639F和Fks1WT的突变引入来自分支III和I的棘白菌素敏感和耐药分离株中。通过临床和实验室标准协会的方法测定棘白菌素敏感性。用荧光增白剂和苯胺蓝染色评估几丁质和β-葡聚糖的细胞壁丰度。
EPIC系统能够在所有测试的耳念珠菌分离株中进行靶向ADE2编辑,并通过测序确认精确编辑。在棘白菌素敏感的分支III分离株中引入了FKS1中的一个单核苷酸多态性(SNP),该SNP导致S639F替代或同义突变。通过全基因组测序确认了EPIC系统对FKS1的精确编辑。引入Fks1S639F等位基因增加了棘白菌素耐药性,而在棘白菌素耐药的分支I分离株中将Fks1S639F校正为Fks1WT序列恢复了棘白菌素敏感性。细胞壁组成评估显示,携带Fks1S639F的菌株含有显著升高的β-葡聚糖和几丁质含量。
这些数据证明了我们的EPIC系统在多种耳念珠菌分支背景中引入SNP的能力,同时揭示了编码S639F的FKS1突变对棘白菌素耐药性的直接影响。